RESUMO
Background@#The European Academy of Allergy and Clinical Immunology guideline for the management of urticaria published in 2018 recommends adding omalizumab as a third-line therapy. However, data on the potential predictive factors of a successful response to omalizumab are limited in Korea. Therefore, this study aimed to perform a retrospective clinical analysis of the effects of omalizumab in a Korean population of patients affected by chronic spontaneous urticaria (CSU). @*Objective@#To investigate factors affecting the effect of omalizumab treatment and identify factors related to its clinical response. @*Methods@#We retrospectively reviewed the clinical records of patients with CSU treated with omalizumab at the single-center dermatology department from February 2018 to August 2020. Omalizumab was administered at a single dose of 150 mg every 4 weeks. Clinical treatment response was assessed using the urticaria activity score summed over 7 days (UAS7) after the fourth, sixth, and 12th omalizumab injections. @*Results@#Twenty-six patients were enrolled in this study. The mean UAS7 at baseline was 16.9 (range, 4∼28). Treatment was completed in seven patients (26.9%). Three patients (11.5%) discontinued treatment because of poor treatment response. Symptoms improved in all patients at the fourth injection (UAS7=3.9, range 0∼10). The second administration of omalizumab showed that the lower the body mass index (BMI), the better the response to treatment (p＜0.05), and a similar trend after an additional injection. @*Conclusion@#The symptoms improved after omalizumab treatment in most patients. Those with a lower BMI and higher total immunoglobulin E levels during long-term treatment showed significantly better treatment responses.
RESUMO
Cutaneous warts are caused by the infection of keratinocytes with human papillomavirus (HPV). Hyperpigmentation is a common condition in which patches of skin become darker than the normal surrounding skin. We report a case of a 56-year-old man who presented with an asymptomatic pinkish and brownish plaque accompanied by progressive pigmentation on the left sole. The lesion was located where the patient had undergone wide excision and skin graft for stage Ib acral lentiginous melanoma three years earlier. Recurrent melanoma (nodular and acral lentiginous type) was suspected, and skin biopsies of the nodular lesion and lentiginous pigmented lesion were performed. The patient was diagnosed with plantar warts with hyperpigmentation by skin biopsy. In this case, damage to the skin barrier at the melanoma site and repeated surgery may have increased the risk of developing verruca and progressive pigmentary changes.
RESUMO
Cutaneous warts are caused by the infection of keratinocytes with human papillomavirus (HPV). Hyperpigmentation is a common condition in which patches of skin become darker than the normal surrounding skin. We report a case of a 56-year-old man who presented with an asymptomatic pinkish and brownish plaque accompanied by progressive pigmentation on the left sole. The lesion was located where the patient had undergone wide excision and skin graft for stage Ib acral lentiginous melanoma three years earlier. Recurrent melanoma (nodular and acral lentiginous type) was suspected, and skin biopsies of the nodular lesion and lentiginous pigmented lesion were performed. The patient was diagnosed with plantar warts with hyperpigmentation by skin biopsy. In this case, damage to the skin barrier at the melanoma site and repeated surgery may have increased the risk of developing verruca and progressive pigmentary changes.